{"id":"W2955764585","doi":"","title":"Безопасность биологических препаратов. Сообщение 2. Проблемы безопасности биоподобных препаратов","year":2016,"lang":"ru","type":"article","venue":"Biological Products Prevention Diagnosis Treatment","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Pharmacovigilance; Medicine; Infliximab; Interchangeability; Ulcerative colitis; Inflammatory bowel disease; Marketing authorization; Disease; Intensive care medicine; Pharmacology; Drug; Internal medicine; Bioinformatics","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001457958,0.0004889398,0.0003673431,0.001660706,0.001399385,0.002202966,0.0005348228,0.001846965,0.0297105],"category_scores_gemma":[0.002220161,0.0007816509,0.00071393,0.001101143,0.001369368,0.001166981,0.0009445093,0.002372422,0.01868257],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001195114,"about_ca_system_score_gemma":0.001794148,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004077377,"about_ca_topic_score_gemma":0.004947756,"domain_scores_codex":[0.9984832,0.0001959471,0.0001054878,0.0002518447,0.000831292,0.0001322766],"domain_scores_gemma":[0.9990086,0.0002546216,0.0001796664,0.0001619188,0.0003197461,0.0000754409],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003593036,0.0001687732,0.001341526,0.001614172,0.00006739538,0.001824789,0.001356449,0.0009839108,0.1623938,0.2538715,0.03226573,0.5437527],"study_design_scores_gemma":[0.00004286287,0.0001202391,0.00229449,0.0001515217,0.00005559975,0.001685336,0.0002144798,0.0004713516,0.04756766,0.01648889,0.9308296,0.00007780531],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"other","genre_gemma":"empirical","genre_scores_codex":[0.05894608,0.08695616,0.1872747,0.0133834,0.008911226,0.0009402064,0.002727996,0.002094366,0.6387658],"genre_scores_gemma":[0.4523464,0.05020865,0.1859086,0.002703141,0.001576788,0.001394118,0.001158365,0.0007682373,0.3039357],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.0297105,"threshold_uncertainty_score":0.09939152,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.105695995460469,"score_gpt":0.3372912321613004,"score_spread":0.2315952367008313,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}